-+ 0.00%
-+ 0.00%
-+ 0.00%

Evercore ISI Group Maintains Outperform on Halozyme Therapeutics, Raises Price Target to $125

Benzinga·11/06/2026 14:49:30
Listen to the news
Evercore ISI Group analyst Michael DiFiore maintains Halozyme Therapeutics (NASDAQ:HALO) with a Outperform and raises the price target from $123 to $125.